Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Onconetix, Inc. stock logo
BWV
Onconetix
$77.50
$0.18
$0.18
$1.95
$1.45B3.58795,235 shs1,999 shs
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$2.38
+8.2%
$2.44
$1.62
$14.67
$5.64M1.09924,076 shs50,752 shs
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
$0.00
$0.00
$0.00
$0.07
$9K-0.068,049 shsN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
$35.25
-0.6%
$37.67
$1.72
$54.30
$215.55M1.11358,021 shs12,005 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Onconetix, Inc. stock logo
BWV
Onconetix
0.00%0.00%0.00%+42,907.77%+42,907.77%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+8.18%-1.65%-27.66%-55.84%-72.16%
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
0.00%0.00%-96.00%+100.00%+100.00%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-0.56%-4.47%-17.47%+12.66%+1,021.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Onconetix, Inc. stock logo
BWV
Onconetix
N/AN/AN/AN/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.1947 of 5 stars
0.02.00.00.03.30.00.0
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.9496 of 5 stars
3.45.00.00.03.02.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Onconetix, Inc. stock logo
BWV
Onconetix
0.00
N/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.00
N/AN/AN/A
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
0.00
N/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.75
Moderate Buy$55.3356.97% Upside

Current Analyst Ratings Breakdown

Latest MNPR, KLDO, BWV, and ENSC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/2/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/1/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
3/19/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$76.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Onconetix, Inc. stock logo
BWV
Onconetix
N/AN/AN/AN/A$1.63 per shareN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$2.23M2.53N/AN/A($3.10) per share-0.77
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
$1.10M0.01N/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/A$1.88 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Onconetix, Inc. stock logo
BWV
Onconetix
-$13.42M-$1.08N/AN/AN/A-108.19%-66.47%N/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$10.61M-$6.54N/AN/AN/A-179.26%-292.81%-158.83%8/13/2025 (Estimated)
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
N/A-$2.24N/AN/AN/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$8.40M-$3.48N/AN/AN/AN/A-107.21%-87.57%8/8/2025 (Estimated)

Latest MNPR, KLDO, BWV, and ENSC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 million
5/13/2025Q1 2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.65-$0.38+$0.27-$0.38N/AN/A
3/31/2025Q4 2024
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.36-$2.23-$1.87-$2.23N/AN/A
3/10/2025Q4 2024
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$2.74-$2.90-$0.16-$2.90$0.25 million$1.30 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Onconetix, Inc. stock logo
BWV
Onconetix
N/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
N/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Onconetix, Inc. stock logo
BWV
Onconetix
N/A
0.54
0.46
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
3.24
3.24
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
N/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/A
5.41
5.41

Institutional Ownership

CompanyInstitutional Ownership
Onconetix, Inc. stock logo
BWV
Onconetix
22.34%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
81.56%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1.83%

Insider Ownership

CompanyInsider Ownership
Onconetix, Inc. stock logo
BWV
Onconetix
19.50%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
7.90%
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
9.00%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
20.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Onconetix, Inc. stock logo
BWV
Onconetix
1218.66 million15.02 millionNot Optionable
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
102.37 million1.20 millionNot Optionable
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
8042.62 million38.79 millionNot Optionable
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
106.12 million3.97 millionNot Optionable

Recent News About These Companies

Research Analysts Set Expectations for MNPR Q2 Earnings
Piper Sandler Remains a Buy on Monopar Therapeutics Inc (MNPR)
Monopar Therapeutics downgraded to Hold from Buy at JonesResearch
JonesTrading downgrades Monopar Therapeutics Inc (MNPR) to a Hold

New MarketBeat Followers Over Time

Media Sentiment Over Time

Onconetix stock logo

Onconetix NASDAQ:BWV

Blue Water Biotech, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Vaccines, Inc. and changed its name to Blue Water Biotech, Inc. in April 2023. Blue Water Biotech, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$2.38 +0.18 (+8.18%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.36 -0.02 (-1.05%)
As of 08:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Kaleido Biosciences stock logo

Kaleido Biosciences NASDAQ:KLDO

$0.0002 0.00 (0.00%)
As of 05/23/2025

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Monopar Therapeutics stock logo

Monopar Therapeutics NASDAQ:MNPR

$35.25 -0.20 (-0.56%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$36.80 +1.55 (+4.40%)
As of 08:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.